Novartis, Amgen and Banner Alzheimer’s Institute, cooperation broadened

Novartis, Amgen and Banner Alzheimer’s Institute (BAI) have announced they have broadened their cooperation. Specifically, the companies have informed they will initiate the API (Alzheimer’s Prevention Initiative) Generation Study 2, designed to assess the CNP520 BACE1 inhibitor in preventing or slowing Alzheimer’s’ symptoms in a high-risk patient population. BACE1 enzym plays a key role in the production of Amyloid Beta. Some patients were already enrolled in August in the US and the trial is likely to include up to 180 sites in more than 20 countries around the world. The study will last five years and will recruit approximately 2,000 participants without cognitive disorders, aged 60 to 75, who, based on genetic analyses, have risk factors for AD. The enrolled patients will be randomized to receive one of two doses of the drug to be tested – 15 or 50mg – or placebo. (Source: Novartis)